Document is current
Any future updates will be listed below
-
Authors
Sano, Junichi
Matsuda, Satoru
Kawakubo, Hirofumi
Takemura, Ryo
Okui, Jun
Irino, Tomoyuki
Fukuda, Kazumasa
Nakamura, Rieko
Kitagawa, Yuko
- License Information
-
More Information
Article History
Received: 10 March 2022
Accepted: 11 March 2022
First Online: 31 March 2022
Disclosures
: Kazumasa Fukuda—I belong to the Keio University School of Medicine Endowed Chair in Cancer Research funded by CHUGAI PHARMACEUTICAL CO., LTD and TAIHO PHARMACEUTICAL CO., LTD. Yuko Kitagawa, relevant financial activities outside the submitted work: Takeda Pharmaceutical Co., Ltd., CHUGAI PHARMACEUTICAL CO., LTD., TAIHO PHARMACEUTICAL CO., LTD, Yakult Honsha Co. Ltd., ASAHI KASEI PHARMA CORPORATION, Otsuka Pharmaceutical Co., Ltd., ONO PHARMACEUTICAL CO., LTD.TSUMURA & CO., Kyouwa Hakkou Kirin Co., Ltd., DAINIPPON SUMITOMO PHARMA Co., Ltd., EA Pharma Co., Ltd., Astellas Pharma Inc., Toyama Chemical Co., Ltd, MEDICON INC., KAKEN PHARMACEUTICAL CO. LTD., Eisai Co., Ltd., Otsuka Pharmaceutical Factory Inc.TEIJIN PHARMA LIMITED, NIHON PHARMACEUTICAL CO., LTD., Nippon Covidien Inc., Otsuka Pharmaceutical Factory Inc., SHIONOGI & CO., LTD., Nippon Covidien Inc., Ethicon, Inc., ONO PHARMACEUTICAL CO., LTD., Olympus Corporation, Bristol-Myers Squibb K.K., AstraZeneca K.K., MSD K.K., Smith & Nephew K.K., KAKEN PHARMACEUTICAL CO. LTD.
